Ashjng personal page - To The Moon

Ashjng

Ashjng

No personal profile

29Follow

5Followers

0Topic

0Badge

2021-03-17

Nice

3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy

2021-03-30

Hi

Sorry, the original content has been removed

2021-03-17

Hi

Sorry, the original content has been removed

2021-04-10

Good good

Netflix Grabs Sony's Pay-TV Movie Deal From Starz

2021-03-17

Ok

After winning with ‘disruptive’ stocks, this five-star manager has a few more ideas to share

07-20

$NVIDIA Corp(NVDA)$

07-20

$NVIDIA Corp(NVDA)$

2021-04-10

Www

XPeng Inc.: A Reawakening

2021-03-17

HaoDe

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3562320683985663","uuid":"3562320683985663","gmtCreate":1599229124952,"gmtModify":1599265717732,"name":"Ashjng","pinyin":"ashjng","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","hatId":"ca_profile_frame_Mpy1eK","hatName":"","vip":1,"status":2,"fanSize":5,"headSize":29,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.71%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.64%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":7,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":329351169003736,"gmtCreate":1721413659545,"gmtModify":1721619619802,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a>&nbsp;","text":"$NVIDIA Corp(NVDA)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329351169003736","isVote":1,"tweetType":1,"viewCount":263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":329350552678648,"gmtCreate":1721413634836,"gmtModify":1721619620396,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a>&nbsp;","text":"$NVIDIA Corp(NVDA)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329350552678648","isVote":1,"tweetType":1,"viewCount":74,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":346392192,"gmtCreate":1617987143716,"gmtModify":1704705738194,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"Good good&nbsp;","listText":"Good good&nbsp;","text":"Good good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/346392192","repostId":"2126315033","repostType":4,"repost":{"id":"2126315033","kind":"highlight","pubTimestamp":1617981660,"share":"https://ttm.financial/m/news/2126315033?lang=&edition=fundamental","pubTime":"2021-04-09 23:21","market":"us","language":"en","title":"Netflix Grabs Sony's Pay-TV Movie Deal From Starz","url":"https://stock-news.laohu8.com/highlight/detail?id=2126315033","media":"Anders Bylund","summary":"Most Hollywood studios have started their own streaming services to compete in the evolving media market. Sony picked a well-established partner instead.","content":"<p>Video-streaming veteran <b>Netflix</b> (NASDAQ:NFLX) just signed a multiyear content deal with <b>Sony</b> (NYSE:SNE) Pictures Entertainment. Starting in 2022, Sony will move its exclusive pay-TV distribution window from longtime partner <a href=\"https://laohu8.com/S/STRZA\">Starz</a> to Netflix, putting the studio's theatrical releases on Netflix's global streaming platform.</p><p>Sony and Netflix already had a streaming agreement for animated content, but this deal expands that partnership to all genres and production types. Titles making their home entertainment premiere in 2022 on Netflix rather than <b>Lions Gate Entertainment</b> (NYSE:LGF-A) (NYSE:LGF-B) subsidiary <a href=\"https://laohu8.com/S/STRZB\">Starz</a> will include the Brad Pitt thriller <i>Bullet Train</i>, the ensemble-cast action movie <i>Uncharted</i>, and the Reese Witherspoon-produced murder drama <i>Where the Crawdads Sing</i>.</p><p><img src=\"https://static.tigerbbs.com/9243727dc46ddf4fb557f7d44eef1325\" tg-width=\"700\" tg-height=\"534\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><p>Netflix will also distribute future titles in Sony's established film franchises such as <i>Venom</i>, <i>Jumanji</i>, and <i>Bad Boys</i>, as well as any other new projects that Sony's several studio brands may come up with. The deal also allows licensing rights for Netflix to show some titles from Sony's enormous back catalog.</p><p>Furthermore, Netflix gets \"first look\" privilege to consider developing any direct-to-streaming titles Sony's studios may develop during this agreement.&nbsp;Netflix has committed to releasing an undisclosed minimum number of such productions, which will add exclusive Sony/Netflix content on top of Sony's continuing theatrical productions.</p><p>The terms of the deal were not disclosed, but Netflix's payments to Sony should be \"record setting\" for a pay-TV distribution window, according to <i>Variety</i>'s anonymous insider sources.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Netflix Grabs Sony's Pay-TV Movie Deal From Starz</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNetflix Grabs Sony's Pay-TV Movie Deal From Starz\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-09 23:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/09/netflix-grabs-sonys-pay-tv-movie-deal-from-starz/><strong>Anders Bylund</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Video-streaming veteran Netflix (NASDAQ:NFLX) just signed a multiyear content deal with Sony (NYSE:SNE) Pictures Entertainment. Starting in 2022, Sony will move its exclusive pay-TV distribution ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/09/netflix-grabs-sonys-pay-tv-movie-deal-from-starz/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NFLX":"奈飞","QNETCN":"纳斯达克中美互联网老虎指数"},"source_url":"https://www.fool.com/investing/2021/04/09/netflix-grabs-sonys-pay-tv-movie-deal-from-starz/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2126315033","content_text":"Video-streaming veteran Netflix (NASDAQ:NFLX) just signed a multiyear content deal with Sony (NYSE:SNE) Pictures Entertainment. Starting in 2022, Sony will move its exclusive pay-TV distribution window from longtime partner Starz to Netflix, putting the studio's theatrical releases on Netflix's global streaming platform.Sony and Netflix already had a streaming agreement for animated content, but this deal expands that partnership to all genres and production types. Titles making their home entertainment premiere in 2022 on Netflix rather than Lions Gate Entertainment (NYSE:LGF-A) (NYSE:LGF-B) subsidiary Starz will include the Brad Pitt thriller Bullet Train, the ensemble-cast action movie Uncharted, and the Reese Witherspoon-produced murder drama Where the Crawdads Sing.Image source: Getty Images.Netflix will also distribute future titles in Sony's established film franchises such as Venom, Jumanji, and Bad Boys, as well as any other new projects that Sony's several studio brands may come up with. The deal also allows licensing rights for Netflix to show some titles from Sony's enormous back catalog.Furthermore, Netflix gets \"first look\" privilege to consider developing any direct-to-streaming titles Sony's studios may develop during this agreement. Netflix has committed to releasing an undisclosed minimum number of such productions, which will add exclusive Sony/Netflix content on top of Sony's continuing theatrical productions.The terms of the deal were not disclosed, but Netflix's payments to Sony should be \"record setting\" for a pay-TV distribution window, according to Variety's anonymous insider sources.","news_type":1},"isVote":1,"tweetType":1,"viewCount":448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":346396833,"gmtCreate":1617986949622,"gmtModify":1704705737226,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"Www","listText":"Www","text":"Www","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/346396833","repostId":"1142324412","repostType":4,"repost":{"id":"1142324412","kind":"news","pubTimestamp":1617982207,"share":"https://ttm.financial/m/news/1142324412?lang=&edition=fundamental","pubTime":"2021-04-09 23:30","market":"us","language":"en","title":"XPeng Inc.: A Reawakening","url":"https://stock-news.laohu8.com/highlight/detail?id=1142324412","media":"seekingalpha","summary":"Valuation is middling but not overvalued like in the past.Recent announcement of capacity expansion in Wuhan lends better operational and sales visibility.Company could breakeven and finally reach positive profits soon; major improvements seen in operating margins.Feared chip shortage  was not a disaster, deliveries are still strong.Government support, China's creation of an EV ecosystem.XPEV's strong deliveries describe not only excellent support from the private sector, but also the Chinese go","content":"<p><b>Summary</b></p>\n<ul>\n <li>Valuation is middling but not overvalued like in the past.</li>\n <li>Recent announcement of capacity expansion in Wuhan lends better operational and sales visibility.</li>\n <li>Company could breakeven and finally reach positive profits soon; major improvements seen in operating margins.</li>\n <li>Feared chip shortage (i.e. supply disruption) was not a disaster, deliveries are still strong.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4e0f3343d69719839f9b8f1d337c3984\" tg-width=\"1536\" tg-height=\"1024\"><span>Photo by Robert Way/iStock Editorial via Getty Images</span></p>\n<p><b>Introduction</b></p>\n<p>The stock price of&nbsp;XPEV&nbsp;has been converging with the performance of the S&amp;P 500 since March 2021, as compared to its massive outperformance in 4Q2020. This could be view positively or negatively. On the bright side, this suggests that price performance would become more predictable with lower volatility, indicative of a broadening consensus on the fundamental prospects of the company. On the other hand, traders may be disappointed its lack of momentum. Therefore, this is probably a good time to stop viewing XPEV as purely a trade, but re-analyze its merits as a fundamentally-driven investment.</p>\n<p><i>The frenetic performance of XPEV has calmed down in recent weeks, allowing its one year performance to track the S&amp;P 500 more closely</i></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9f04001d604ecc7892ef3a76c498578b\" tg-width=\"640\" tg-height=\"236\"><span>Source: SeekingAlpha</span></p>\n<p><i>XPEV's G3 Super Long Range Smart SUV</i></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/68446a741f9f97afc10f2149c4e13e13\" tg-width=\"640\" tg-height=\"388\"><span>Source: XPeng Motors (G3、P7) Intelligent electric car with Internet DNA</span></p>\n<p><b>Industry and commercial positives</b></p>\n<p>Optimism on EVs and&nbsp;strong industry growth&nbsp;rates are common knowledge by now. The following points suggest specific positives for XPEV that remain intact despite relatively ebbing momentum on the stock's price (as compared to 4Q2020):</p>\n<ol>\n <li><b>Deliveries met despite fears on chip shortage.</b>While the stock's price momentum appears to have ebbed, recent news continues to remain positive. At an industry level, Chinese vehicle manufacturers XPEV andNIOmanaged to manufacture the expected numbers of vehicle deliveries, despite much feared chip shortages.XPEV chalked&nbsp;in record quarterly deliveries of 13,340 EVs in Q1 2021, +487% over the year and +130% over the month in March.NIO delivered&nbsp;20,060 +423% over the year while Q1 deliveries rose 15.6% to 20,060. The challenge these EV manufacturers face now is not so much the ability to deliver on its numbers, but on being able to meet high expectations for the stock price to gain further traction.</li>\n <li><b>Government support, China's creation of an EV ecosystem.</b>XPEV's strong deliveries describe not only excellent support from the private sector, but also the Chinese government's push to develop this part of its industry. XPEV has entered into an agreement with the city of Wuhan to build a factory with a capacity of 100,000 EV units. This is a very significant piece of news, considering its deliveries of just 5,102 in March 2021. Annualizing this number, the new capacity will be more than the whole of XPEV's total historical annual production. This news is interesting and significant since it was just released this week, suggesting it may have yet to be factored into analysts' forecast numbers. This is made more important as XPEV has always been considered a laggard in production capabilities to its larger cousin NIO. General Chinese government support for the EV ecosystem is strong, and the new facility in Wuhan echoes earlier provincial government financial support ($77m) in Guangdong. The reality is, for EVs to gain traction, government willingness to support infrastructure initiatives are highly important (e.g. permits for charging stations, creating incentives to convert from old polluting vehicles to green vehicles, etc.). With China's tradition of central planning, the EV ecosystem is placed on the right footing.</li>\n <li><b>Listing in Hong Kong adds to investor base and liquidity.</b>Going forward,XPEV,NIO, and&nbsp;LI&nbsp;intend tolistin Hong Kong this year. This is a strategic move, and makes the valuation of these companies less susceptible by US political bashing (e.g. the threat of being de-listed) should it occur, since it reflects a wider geographical base. The valuations of these companies may even get a boost given greater global liquidity due to added trading in the Asian time zone.</li>\n</ol>\n<p>Of note, in late March, XPEV held an&nbsp;autonomous driving expedition&nbsp;covering eight cities in China and 3,675 kilometers. The exercise was successful, as minimal human intervention was needed during the expedition and adds another brownie point to XPEV's research and development efforts, placing XPEV on the&nbsp;competitive landscape&nbsp;against rivals such as TSLA and NIO on autonomous driving. Apparently, XPEV's autonomous driving results&nbsp;performed better&nbsp;than TSLA's with fewer human interventions per 100km and better navigation in complex situations.</p>\n<p><b>XPEV's improving financials</b></p>\n<p>Now that we have several quarters of financial data on XPEV, it is worth reviewing how its metrics have been performing. Firstly, market expectations aside, deliveries have been very good as abovementioned, and this is flowing through to revenue numbers. As shown in the below table, growth has been very strong, and revenues are expected to more than double in 2021 and continue to double in 2022. Such growth rates place XPEV at the top end of manufacturing firms, as expected of the fast-growing EV market.</p>\n<p>Another point to note is the improvement in operating margins. As with any \"new tech\" company, initial investments would cause hugely negative operating margins in the beginning. What's important is the company's ability to improve margins and reduce costs over time. In this respect, XPEV has done a good job, with operating margins improving sequentially each quarter. Of note, operating margins started to see major improvements between the Jun-2020 (-142%) and Dec-2020 (-39%) quarters as shown in the table below. Given this trend, the company is likely to breakeven and register positive profits soon, which could be a catalytic re-rating for XPEV. When we pair this analysis with the stock price, it appears that XPEV's recently soft stock price performance is not justified.</p>\n<p>Meanwhile, the balance sheet is expected to remain strong. Equity to total liabilities &amp; equity is 23% as at Dec-2020. As abovementioned, further capital raises with a forthcoming Hong Kong listing will add to XPEV's cash buffer.</p>\n<p><i>XPEV's performance improvement in both revenue and operating margin trends appear to have been ignored by the market due to recent the broad market capitulation</i></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f8258dce0cc10e8118a23afce7655bed\" tg-width=\"726\" tg-height=\"737\"><span>*EST = estimate by analysts' consensus from SeekingAlpha</span></p>\n<p><b>XPEV's valuation: somewhere in the middle</b></p>\n<p>XPEV's stock price has done well over the last 6 months versus peers. On a TTM P/S, XPEV is near the middle although its FWD P/S is trading at a premium. However, there could be a general re-rating of the P/S of the sector if the Chinese EV manufacturers reach breakeven in 2021 and record positive profits (our base case belief, given the prevailing trend in XPEV's improving operating margins). This will then allow better price discovery when the companies can then be valued on their P/E ratios.</p>\n<img src=\"https://static.tigerbbs.com/fa975ce545e950a20f809bcc7f698ef6\" tg-width=\"911\" tg-height=\"594\">\n<table>\n <tbody>\n  <tr></tr>\n </tbody>\n</table>\n<p><b>Conclusion and Risks</b></p>\n<p>XPEV's stock price may benefit from two key catalysts: (1) expansion of manufacturing facility in Wuhan, which will concretely raise visibility of revenue growth which is expected to double; (2) a valuation regime change as it progresses from a loss making company to a profitable one, expected by this year. Furthermore, it is worth noting that the valuation is not lofty as compared to price levels in 4Q2020, having fallen over the last couple of months.</p>\n<p>Competition may exist and remain intense, but given the large size of China's market and that there are only a couple of notable players (i.e. NIO, LI), the market remains largely an oligopoly which allows XPEV to retain pricing power.</p>\n<p>Much feared risks of execution in the past appear to have materialized but not in a big way, i.e. the previously expected chip shortage. Given the progression to a post-COVID economy, supply chain links should improve and reduce similar risks in the future.</p>\n<p>On a standalone basis, XPEV's prospects appear bright, and now the key hurdle is whether the NASDAQ will find momentum and exceed previous highs. The base case for this should lean towards the positive as the market is merely in the first year of the economic recovery after the pandemic. Recent price consolidation appears to have created a technical setup for a reawakening of price momentum as consumer activity revives post-pandemic.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XPeng Inc.: A Reawakening</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXPeng Inc.: A Reawakening\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-09 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4418326-xpeng-inc-reawakening><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nValuation is middling but not overvalued like in the past.\nRecent announcement of capacity expansion in Wuhan lends better operational and sales visibility.\nCompany could breakeven and ...</p>\n\n<a href=\"https://seekingalpha.com/article/4418326-xpeng-inc-reawakening\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车"},"source_url":"https://seekingalpha.com/article/4418326-xpeng-inc-reawakening","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1142324412","content_text":"Summary\n\nValuation is middling but not overvalued like in the past.\nRecent announcement of capacity expansion in Wuhan lends better operational and sales visibility.\nCompany could breakeven and finally reach positive profits soon; major improvements seen in operating margins.\nFeared chip shortage (i.e. supply disruption) was not a disaster, deliveries are still strong.\n\nPhoto by Robert Way/iStock Editorial via Getty Images\nIntroduction\nThe stock price of XPEV has been converging with the performance of the S&P 500 since March 2021, as compared to its massive outperformance in 4Q2020. This could be view positively or negatively. On the bright side, this suggests that price performance would become more predictable with lower volatility, indicative of a broadening consensus on the fundamental prospects of the company. On the other hand, traders may be disappointed its lack of momentum. Therefore, this is probably a good time to stop viewing XPEV as purely a trade, but re-analyze its merits as a fundamentally-driven investment.\nThe frenetic performance of XPEV has calmed down in recent weeks, allowing its one year performance to track the S&P 500 more closely\nSource: SeekingAlpha\nXPEV's G3 Super Long Range Smart SUV\nSource: XPeng Motors (G3、P7) Intelligent electric car with Internet DNA\nIndustry and commercial positives\nOptimism on EVs and strong industry growth rates are common knowledge by now. The following points suggest specific positives for XPEV that remain intact despite relatively ebbing momentum on the stock's price (as compared to 4Q2020):\n\nDeliveries met despite fears on chip shortage.While the stock's price momentum appears to have ebbed, recent news continues to remain positive. At an industry level, Chinese vehicle manufacturers XPEV andNIOmanaged to manufacture the expected numbers of vehicle deliveries, despite much feared chip shortages.XPEV chalked in record quarterly deliveries of 13,340 EVs in Q1 2021, +487% over the year and +130% over the month in March.NIO delivered 20,060 +423% over the year while Q1 deliveries rose 15.6% to 20,060. The challenge these EV manufacturers face now is not so much the ability to deliver on its numbers, but on being able to meet high expectations for the stock price to gain further traction.\nGovernment support, China's creation of an EV ecosystem.XPEV's strong deliveries describe not only excellent support from the private sector, but also the Chinese government's push to develop this part of its industry. XPEV has entered into an agreement with the city of Wuhan to build a factory with a capacity of 100,000 EV units. This is a very significant piece of news, considering its deliveries of just 5,102 in March 2021. Annualizing this number, the new capacity will be more than the whole of XPEV's total historical annual production. This news is interesting and significant since it was just released this week, suggesting it may have yet to be factored into analysts' forecast numbers. This is made more important as XPEV has always been considered a laggard in production capabilities to its larger cousin NIO. General Chinese government support for the EV ecosystem is strong, and the new facility in Wuhan echoes earlier provincial government financial support ($77m) in Guangdong. The reality is, for EVs to gain traction, government willingness to support infrastructure initiatives are highly important (e.g. permits for charging stations, creating incentives to convert from old polluting vehicles to green vehicles, etc.). With China's tradition of central planning, the EV ecosystem is placed on the right footing.\nListing in Hong Kong adds to investor base and liquidity.Going forward,XPEV,NIO, and LI intend tolistin Hong Kong this year. This is a strategic move, and makes the valuation of these companies less susceptible by US political bashing (e.g. the threat of being de-listed) should it occur, since it reflects a wider geographical base. The valuations of these companies may even get a boost given greater global liquidity due to added trading in the Asian time zone.\n\nOf note, in late March, XPEV held an autonomous driving expedition covering eight cities in China and 3,675 kilometers. The exercise was successful, as minimal human intervention was needed during the expedition and adds another brownie point to XPEV's research and development efforts, placing XPEV on the competitive landscape against rivals such as TSLA and NIO on autonomous driving. Apparently, XPEV's autonomous driving results performed better than TSLA's with fewer human interventions per 100km and better navigation in complex situations.\nXPEV's improving financials\nNow that we have several quarters of financial data on XPEV, it is worth reviewing how its metrics have been performing. Firstly, market expectations aside, deliveries have been very good as abovementioned, and this is flowing through to revenue numbers. As shown in the below table, growth has been very strong, and revenues are expected to more than double in 2021 and continue to double in 2022. Such growth rates place XPEV at the top end of manufacturing firms, as expected of the fast-growing EV market.\nAnother point to note is the improvement in operating margins. As with any \"new tech\" company, initial investments would cause hugely negative operating margins in the beginning. What's important is the company's ability to improve margins and reduce costs over time. In this respect, XPEV has done a good job, with operating margins improving sequentially each quarter. Of note, operating margins started to see major improvements between the Jun-2020 (-142%) and Dec-2020 (-39%) quarters as shown in the table below. Given this trend, the company is likely to breakeven and register positive profits soon, which could be a catalytic re-rating for XPEV. When we pair this analysis with the stock price, it appears that XPEV's recently soft stock price performance is not justified.\nMeanwhile, the balance sheet is expected to remain strong. Equity to total liabilities & equity is 23% as at Dec-2020. As abovementioned, further capital raises with a forthcoming Hong Kong listing will add to XPEV's cash buffer.\nXPEV's performance improvement in both revenue and operating margin trends appear to have been ignored by the market due to recent the broad market capitulation\n*EST = estimate by analysts' consensus from SeekingAlpha\nXPEV's valuation: somewhere in the middle\nXPEV's stock price has done well over the last 6 months versus peers. On a TTM P/S, XPEV is near the middle although its FWD P/S is trading at a premium. However, there could be a general re-rating of the P/S of the sector if the Chinese EV manufacturers reach breakeven in 2021 and record positive profits (our base case belief, given the prevailing trend in XPEV's improving operating margins). This will then allow better price discovery when the companies can then be valued on their P/E ratios.\n\n\n\n\n\n\nConclusion and Risks\nXPEV's stock price may benefit from two key catalysts: (1) expansion of manufacturing facility in Wuhan, which will concretely raise visibility of revenue growth which is expected to double; (2) a valuation regime change as it progresses from a loss making company to a profitable one, expected by this year. Furthermore, it is worth noting that the valuation is not lofty as compared to price levels in 4Q2020, having fallen over the last couple of months.\nCompetition may exist and remain intense, but given the large size of China's market and that there are only a couple of notable players (i.e. NIO, LI), the market remains largely an oligopoly which allows XPEV to retain pricing power.\nMuch feared risks of execution in the past appear to have materialized but not in a big way, i.e. the previously expected chip shortage. Given the progression to a post-COVID economy, supply chain links should improve and reduce similar risks in the future.\nOn a standalone basis, XPEV's prospects appear bright, and now the key hurdle is whether the NASDAQ will find momentum and exceed previous highs. The base case for this should lean towards the positive as the market is merely in the first year of the economic recovery after the pandemic. Recent price consolidation appears to have created a technical setup for a reawakening of price momentum as consumer activity revives post-pandemic.","news_type":1},"isVote":1,"tweetType":1,"viewCount":145,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":355124426,"gmtCreate":1617040586865,"gmtModify":1704801263777,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/355124426","repostId":"2123590172","repostType":4,"repost":{"id":"2123590172","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1617030981,"share":"https://ttm.financial/m/news/2123590172?lang=&edition=fundamental","pubTime":"2021-03-29 23:16","market":"us","language":"en","title":"A Look Into Credit Suisse Group's Price Over Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2123590172","media":"Benzinga","summary":" ","content":"<p>Looking into the current session, <b>Credit Suisse Group Inc. </b>(NYSE:CS) is trading at $11.20, after a 12.91% decrease. Over the past month, the stock fell by 21.29%, but over the past year, it actually increased by 38.45%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.</p>\n<p>Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 25<b>.08%</b>.</p>\n<p><img src=\"https://static.tigerbbs.com/6c3d015235257ee54e197b7a11999931\" tg-width=\"600\" tg-height=\"600\" referrerpolicy=\"no-referrer\"></p>\n<p>The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.</p>\n<p>Most often, an industry will prevail in a particular phase of a business cycle, than other industries.</p>\n<p>Credit Suisse Group Inc. has a lower P/E than the aggregate P/E of <b>36.98</b> of the Capital Markets industry. Ideally, <a href=\"https://laohu8.com/S/AONE\">one</a> might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued.</p>\n<p><img src=\"https://www.benzinga.com/files/images/story/2021/1617030835_1.png\" tg-width=\"700\" tg-height=\"500\" referrerpolicy=\"no-referrer\"></p>\n<p>P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors can become unable to attain key insights from trailing earnings.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look Into Credit Suisse Group's Price Over Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look Into Credit Suisse Group's Price Over Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-03-29 23:16</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Looking into the current session, <b>Credit Suisse Group Inc. </b>(NYSE:CS) is trading at $11.20, after a 12.91% decrease. Over the past month, the stock fell by 21.29%, but over the past year, it actually increased by 38.45%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.</p>\n<p>Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 25<b>.08%</b>.</p>\n<p><img src=\"https://static.tigerbbs.com/6c3d015235257ee54e197b7a11999931\" tg-width=\"600\" tg-height=\"600\" referrerpolicy=\"no-referrer\"></p>\n<p>The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.</p>\n<p>Most often, an industry will prevail in a particular phase of a business cycle, than other industries.</p>\n<p>Credit Suisse Group Inc. has a lower P/E than the aggregate P/E of <b>36.98</b> of the Capital Markets industry. Ideally, <a href=\"https://laohu8.com/S/AONE\">one</a> might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued.</p>\n<p><img src=\"https://www.benzinga.com/files/images/story/2021/1617030835_1.png\" tg-width=\"700\" tg-height=\"500\" referrerpolicy=\"no-referrer\"></p>\n<p>P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors can become unable to attain key insights from trailing earnings.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/69af882c29a3ff047224139fe1096d17","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2123590172","content_text":"Looking into the current session, Credit Suisse Group Inc. (NYSE:CS) is trading at $11.20, after a 12.91% decrease. Over the past month, the stock fell by 21.29%, but over the past year, it actually increased by 38.45%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.\nAssuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 25.08%.\n\nThe P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.\nMost often, an industry will prevail in a particular phase of a business cycle, than other industries.\nCredit Suisse Group Inc. has a lower P/E than the aggregate P/E of 36.98 of the Capital Markets industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued.\n\nP/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors can become unable to attain key insights from trailing earnings.","news_type":1},"isVote":1,"tweetType":1,"viewCount":115,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":324884023,"gmtCreate":1615983079762,"gmtModify":1704789278671,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/324884023","repostId":"1179979737","repostType":4,"repost":{"id":"1179979737","kind":"news","pubTimestamp":1615996440,"share":"https://ttm.financial/m/news/1179979737?lang=&edition=fundamental","pubTime":"2021-03-17 23:54","market":"us","language":"en","title":"Olo opens for trading at $31.82 up 27% from IPO price","url":"https://stock-news.laohu8.com/highlight/detail?id=1179979737","media":"marketwatch","summary":"(March 17) Olo opens for trading at $31.82 up 27% from IPO price.Olo Inc., which makes online-orderi","content":"<p>(March 17)&nbsp;Olo opens for trading at $31.82 up 27% from IPO price.</p><p><img src=\"https://static.tigerbbs.com/20d1f9f9ba6dea497eb21c0f36654a28\" tg-width=\"662\" tg-height=\"438\"></p><p>Olo Inc., which makes online-ordering technology for restaurants, is set to go public Wednesday as it seeks to benefit from an on-demand boom that was helped further along by the coronavirus pandemic.</p><p>The New York-based company priced its initial public offering at $25 a share late Tuesday, much higher than its original target of $16 to $18 a share, which it raised to $20 to $22 a share Monday. It is offering 18 million shares and could raise up to $450 million at a valuation of $3.6 billion.</p><p>The company’s stock will list on the New York Stock Exchange under the ticker symbol OLO, .</p><p>Olo, which was founded in 2005 and is short for “online ordering,” powers 1.8 million orders a day for well-known restaurant chains such as Denny’s, the Cheesecake Factory, Shake Shack and more, as well as Peet’s Coffee, Jamba Juice and others. The company’s revenue surged 94% in 2020 year over year, it said in a filing with the Securities and Exchange Commission.</p><p>“As consumers have become accustomed to the immediate convenience of on-demand commerce, they are demanding the same digital experience from restaurants, placing significant pressure on restaurants to deploy solutions,” Olo said. “This demand has only accelerated since the onset of COVID-19, as on-demand commerce has become a necessity for the majority of restaurants.”</p><p>Olo said that as of Dec. 31, it had about 400 brand partners and its technology — which includes digital ordering and enabling delivery — was being used at more than 64,000 locations.</p><p>The company reported net income of $3.1 million on revenue of $98.4 million last year, compared with a net loss of $8.3 million on revenue of $50.7 million in 2019.</p><p>Olo raised less than $100 million since its inception, it said, including from investors such as The Raine Group, Tiger Global Management and RRE Ventures.</p><p>The IPO will be led by Goldman Sachs and J.P. Morgan, two of eight underwriters listed in the filing.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Olo opens for trading at $31.82 up 27% from IPO price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOlo opens for trading at $31.82 up 27% from IPO price\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-17 23:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/olo-maker-of-restaurant-ordering-tech-prices-ipo-at-25-a-share-for-valuation-above-3-billion-11615945340?siteid=yhoof2><strong>marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(March 17) Olo opens for trading at $31.82 up 27% from IPO price.Olo Inc., which makes online-ordering technology for restaurants, is set to go public Wednesday as it seeks to benefit from an on-...</p>\n\n<a href=\"https://www.marketwatch.com/story/olo-maker-of-restaurant-ordering-tech-prices-ipo-at-25-a-share-for-valuation-above-3-billion-11615945340?siteid=yhoof2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OLO":"PowerShares DB Crude Oil Long ET"},"source_url":"https://www.marketwatch.com/story/olo-maker-of-restaurant-ordering-tech-prices-ipo-at-25-a-share-for-valuation-above-3-billion-11615945340?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1179979737","content_text":"(March 17) Olo opens for trading at $31.82 up 27% from IPO price.Olo Inc., which makes online-ordering technology for restaurants, is set to go public Wednesday as it seeks to benefit from an on-demand boom that was helped further along by the coronavirus pandemic.The New York-based company priced its initial public offering at $25 a share late Tuesday, much higher than its original target of $16 to $18 a share, which it raised to $20 to $22 a share Monday. It is offering 18 million shares and could raise up to $450 million at a valuation of $3.6 billion.The company’s stock will list on the New York Stock Exchange under the ticker symbol OLO, .Olo, which was founded in 2005 and is short for “online ordering,” powers 1.8 million orders a day for well-known restaurant chains such as Denny’s, the Cheesecake Factory, Shake Shack and more, as well as Peet’s Coffee, Jamba Juice and others. The company’s revenue surged 94% in 2020 year over year, it said in a filing with the Securities and Exchange Commission.“As consumers have become accustomed to the immediate convenience of on-demand commerce, they are demanding the same digital experience from restaurants, placing significant pressure on restaurants to deploy solutions,” Olo said. “This demand has only accelerated since the onset of COVID-19, as on-demand commerce has become a necessity for the majority of restaurants.”Olo said that as of Dec. 31, it had about 400 brand partners and its technology — which includes digital ordering and enabling delivery — was being used at more than 64,000 locations.The company reported net income of $3.1 million on revenue of $98.4 million last year, compared with a net loss of $8.3 million on revenue of $50.7 million in 2019.Olo raised less than $100 million since its inception, it said, including from investors such as The Raine Group, Tiger Global Management and RRE Ventures.The IPO will be led by Goldman Sachs and J.P. Morgan, two of eight underwriters listed in the filing.","news_type":1},"isVote":1,"tweetType":1,"viewCount":370,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":325469037,"gmtCreate":1615914491529,"gmtModify":1704788476601,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"HaoDe","listText":"HaoDe","text":"HaoDe","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/325469037","repostId":"1103230244","repostType":4,"repost":{"id":"1103230244","kind":"news","pubTimestamp":1615905880,"share":"https://ttm.financial/m/news/1103230244?lang=&edition=fundamental","pubTime":"2021-03-16 22:44","market":"us","language":"en","title":"AMC pulls back 10% after big Monday gain; Cinemas, Reddit stocks slip","url":"https://stock-news.laohu8.com/highlight/detail?id=1103230244","media":"seekingalpha","summary":"AMC Entertainment (NYSE:AMC) is10.3%lower in some apparent profit-taking today, though it's also mov","content":"<p>AMC Entertainment&nbsp;(NYSE:AMC)&nbsp;is10.3%lower in some apparent profit-taking today, though it's also moving lower in line both withReddit-fave peers and fellow cinema stocks.</p><p>AMC ended upjumping 25.8%yesterday as itreopened its two key Los Angeles venues and reaffirmed its plans to reopen all California locations this weekend.</p><p>That follows Los Angeles Countygranting permission for theaters to reopen, though at just 25% capacity.</p><p>So AMC was ripe for a pullback today. Cinema peers are generally lower too, though: Cinemark(NYSE:CNK)-2.3%;IMAX-9.1%; Marcus(NYSE:MCS)-1.2%; Reading International(NASDAQ:RDI)-0.8%; National CineMedia&nbsp;(NASDAQ:NCMI)&nbsp;-4%. Foreign cinema holdings are higher: Regal owner Cineworld (CNNWF+4.7%); Cineplex(OTCPK:CPXGF)+0.2%.</p><p>And AMC's Reddit-fave peers are also seeing some sharp moves down: GameStop(NYSE:GME)-16.8%; Express(NYSE:EXPR)-11%; Koss(NASDAQ:KOSS)-6.6%.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC pulls back 10% after big Monday gain; Cinemas, Reddit stocks slip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC pulls back 10% after big Monday gain; Cinemas, Reddit stocks slip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-16 22:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3673162-amc-pulls-back-after-big-monday-gain-cinemas-reddit-stocks-slip><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AMC Entertainment (NYSE:AMC) is10.3%lower in some apparent profit-taking today, though it's also moving lower in line both withReddit-fave peers and fellow cinema stocks.AMC ended upjumping 25.8%...</p>\n\n<a href=\"https://seekingalpha.com/news/3673162-amc-pulls-back-after-big-monday-gain-cinemas-reddit-stocks-slip\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://seekingalpha.com/news/3673162-amc-pulls-back-after-big-monday-gain-cinemas-reddit-stocks-slip","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1103230244","content_text":"AMC Entertainment (NYSE:AMC) is10.3%lower in some apparent profit-taking today, though it's also moving lower in line both withReddit-fave peers and fellow cinema stocks.AMC ended upjumping 25.8%yesterday as itreopened its two key Los Angeles venues and reaffirmed its plans to reopen all California locations this weekend.That follows Los Angeles Countygranting permission for theaters to reopen, though at just 25% capacity.So AMC was ripe for a pullback today. Cinema peers are generally lower too, though: Cinemark(NYSE:CNK)-2.3%;IMAX-9.1%; Marcus(NYSE:MCS)-1.2%; Reading International(NASDAQ:RDI)-0.8%; National CineMedia (NASDAQ:NCMI) -4%. Foreign cinema holdings are higher: Regal owner Cineworld (CNNWF+4.7%); Cineplex(OTCPK:CPXGF)+0.2%.And AMC's Reddit-fave peers are also seeing some sharp moves down: GameStop(NYSE:GME)-16.8%; Express(NYSE:EXPR)-11%; Koss(NASDAQ:KOSS)-6.6%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":259,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":325460875,"gmtCreate":1615914350997,"gmtModify":1704788475794,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/325460875","repostId":"1178891078","repostType":4,"repost":{"id":"1178891078","kind":"news","pubTimestamp":1615909549,"share":"https://ttm.financial/m/news/1178891078?lang=&edition=fundamental","pubTime":"2021-03-16 23:45","market":"us","language":"en","title":"3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=1178891078","media":"Benzinga","summary":"Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on M","content":"<p><b>Roche Holding AG</b>RHHBY 0.17%acquired<b>GenMark Diagnostics, Inc</b>(NASDAQ:&nbsp;GNMK) in a$1.8 billion deal&nbsp;on Monday, the same day&nbsp;<b>Veracyte Inc</b>&nbsp;VCYT 1.76%announcedit completed the&nbsp;acquisition of<b>Decipher Biosciences, Inc.</b></p>\n<p><b>What Happened:</b>With thecancer diagnostic marketexpected to grow to $261.34 billion by 2027 — more than double the $115.60 billion it was worth last year — big biotech companies have been on an acquisition spree to boost their portfolios and&nbsp;technology.</p>\n<p>In January,&nbsp;<b>Exact Sciences Corporation</b>&nbsp;EXAS 3.64%announcedit completed its acquisition of<b>Thrive Earlier Detection Corp.</b>and&nbsp;got Thrive’s&nbsp;blood-based multi-cancer detection technology.</p>\n<p><b>Why It Matters:</b>Early detection of cancer greatly increases the survival rate and smaller biotech companies are showing leadership skills in developing the necessary technology.</p>\n<p>Smaller companies develop specific technology for specific types of cancer which allows them to focus on creating tailored products that are also&nbsp;attractive for larger companies&nbsp;to acquire.</p>\n<p>The following three companies have developed technology that could make them sought-after acquisition targets:</p>\n<p><b>BioMark&nbsp;Diagnostics Inc</b>BMKDF 13.17%, a biotech company headquartered in Vancouver, British Columbia, has developed a state-of-the-art liquid biopsy technology platform for the early detection of cancer. The unique technologyfinds metabolomicsbiomarkers of hard-to-detect cancers of the lung, brain, ovarian and pancreas.</p>\n<p>BioMark&nbsp;is pivoting into commercialization after many years in the research and development phase. On Feb. 16, the company&nbsp;announced&nbsp;it will collaborate with&nbsp;Phytronix&nbsp;Technologies Inc “to advance the development of&nbsp;BioMark’s&nbsp;early lung cancer screening applications using&nbsp;Phytronix-proprietary Laser Diode Thermal Desorption (LDTD) technology,”&nbsp;BioMark&nbsp;said in a press release.</p>\n<p>The collaboration will also support&nbsp;BioMark&nbsp;in setting up clinical lab services in Quebec.&nbsp;BioMark&nbsp;plans to demonstrate its technology later in 2021.</p>\n<p>BioMark’s&nbsp;market cap is $28.67 million and its shares are at 41 cents, up 13.17% on Tuesday morning.</p>\n<p><b>Biocept Inc</b>BIOC 0.17%is another company focusing on early cancer detection through blood-based liquid biopsy. The San Diego-based company has two platforms, CTC&nbsp;and&nbsp;ctDNA, used to detect and analyze a patient’s blood for cancer cells and mutations.</p>\n<p>Biocept boasts22 patentsfor its liquid-biopsy technology in the U.S., EU, Australia, China, Japan and South Korea.</p>\n<p>On Feb. 16, Bioceptannounced&nbsp;its product, Target Selector, is ultra-sensitive and capable of detecting mutations using biopsy specimens&nbsp;usually be deemed “quantity not sufficient.”</p>\n<p>In a pivot brought on by the pandemic, Biocept alsoannounced&nbsp;on Feb. 3&nbsp;its lab had processed 250 000 COVID-19 tests using its RT-PCR technology.</p>\n<p>Biocept has a market cap of $79.98 million and the company's&nbsp;shares are at $5.87, down 1.68% Tuesday morning.</p>\n<p><b>HTG Molecular Diagnostics Inc</b>HTGM 3.29%, an Arizona-based biotech company, developed the EdgeSeq&nbsp;Oncology Biomarker Panel to detect colon, breast, prostate and lung cancer from tumor tissue. The analysis tool can detect2,549 genesassociated with tumor biology and results are available only 36 hours following the biopsy collection.</p>\n<p>Unlike&nbsp;BioMark&nbsp;and Biocept, HTG Molecular uses Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens to test for cancers.</p>\n<p>On Feb. 26, HTG Molecularannouncedits&nbsp;EdgeSeq&nbsp;technology “demonstrated the ability to generate unique gene expression profiles for multiple cancer indications” and the amount of tissue required in the samples was 4 to 8 times less than required for similar tests.</p>\n<p>HTG Molecular has a market cap of $28.82 million and its shares area t $6.17, up 1.48% on Tuesday morning.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-16 23:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on Monday, the same day Veracyte Inc VCYT 1.76%announcedit completed the acquisition ofDecipher ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178891078","content_text":"Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on Monday, the same day Veracyte Inc VCYT 1.76%announcedit completed the acquisition ofDecipher Biosciences, Inc.\nWhat Happened:With thecancer diagnostic marketexpected to grow to $261.34 billion by 2027 — more than double the $115.60 billion it was worth last year — big biotech companies have been on an acquisition spree to boost their portfolios and technology.\nIn January, Exact Sciences Corporation EXAS 3.64%announcedit completed its acquisition ofThrive Earlier Detection Corp.and got Thrive’s blood-based multi-cancer detection technology.\nWhy It Matters:Early detection of cancer greatly increases the survival rate and smaller biotech companies are showing leadership skills in developing the necessary technology.\nSmaller companies develop specific technology for specific types of cancer which allows them to focus on creating tailored products that are also attractive for larger companies to acquire.\nThe following three companies have developed technology that could make them sought-after acquisition targets:\nBioMark Diagnostics IncBMKDF 13.17%, a biotech company headquartered in Vancouver, British Columbia, has developed a state-of-the-art liquid biopsy technology platform for the early detection of cancer. The unique technologyfinds metabolomicsbiomarkers of hard-to-detect cancers of the lung, brain, ovarian and pancreas.\nBioMark is pivoting into commercialization after many years in the research and development phase. On Feb. 16, the company announced it will collaborate with Phytronix Technologies Inc “to advance the development of BioMark’s early lung cancer screening applications using Phytronix-proprietary Laser Diode Thermal Desorption (LDTD) technology,” BioMark said in a press release.\nThe collaboration will also support BioMark in setting up clinical lab services in Quebec. BioMark plans to demonstrate its technology later in 2021.\nBioMark’s market cap is $28.67 million and its shares are at 41 cents, up 13.17% on Tuesday morning.\nBiocept IncBIOC 0.17%is another company focusing on early cancer detection through blood-based liquid biopsy. The San Diego-based company has two platforms, CTC and ctDNA, used to detect and analyze a patient’s blood for cancer cells and mutations.\nBiocept boasts22 patentsfor its liquid-biopsy technology in the U.S., EU, Australia, China, Japan and South Korea.\nOn Feb. 16, Bioceptannounced its product, Target Selector, is ultra-sensitive and capable of detecting mutations using biopsy specimens usually be deemed “quantity not sufficient.”\nIn a pivot brought on by the pandemic, Biocept alsoannounced on Feb. 3 its lab had processed 250 000 COVID-19 tests using its RT-PCR technology.\nBiocept has a market cap of $79.98 million and the company's shares are at $5.87, down 1.68% Tuesday morning.\nHTG Molecular Diagnostics IncHTGM 3.29%, an Arizona-based biotech company, developed the EdgeSeq Oncology Biomarker Panel to detect colon, breast, prostate and lung cancer from tumor tissue. The analysis tool can detect2,549 genesassociated with tumor biology and results are available only 36 hours following the biopsy collection.\nUnlike BioMark and Biocept, HTG Molecular uses Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens to test for cancers.\nOn Feb. 26, HTG Molecularannouncedits EdgeSeq technology “demonstrated the ability to generate unique gene expression profiles for multiple cancer indications” and the amount of tissue required in the samples was 4 to 8 times less than required for similar tests.\nHTG Molecular has a market cap of $28.82 million and its shares area t $6.17, up 1.48% on Tuesday morning.","news_type":1},"isVote":1,"tweetType":1,"viewCount":377,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":325460094,"gmtCreate":1615914302918,"gmtModify":1704788475955,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/325460094","repostId":"1115937529","repostType":4,"repost":{"id":"1115937529","kind":"news","pubTimestamp":1615909804,"share":"https://ttm.financial/m/news/1115937529?lang=&edition=fundamental","pubTime":"2021-03-16 23:50","market":"us","language":"en","title":"After winning with ‘disruptive’ stocks, this five-star manager has a few more ideas to share","url":"https://stock-news.laohu8.com/highlight/detail?id=1115937529","media":"marketwatch","summary":"Pacira BioSciences, Planet Fitness and Lyft are among the next hottest stocks, says Macquarie’s Alex","content":"<blockquote>Pacira BioSciences, Planet Fitness and Lyft are among the next hottest stocks, says Macquarie’s Alexander Ely.</blockquote><p>The world is about to step out of a dark hole and into the bright sunshine, so investors should drop the anxiety already.</p><p>That is the message from Alexander Ely, chief investment officer of U.S. equity growth at Macquarie Investment Management. “The economy is reopening, it’s doing great. We’re coming out of a pandemic. It’s going to be awesome,” he told MarketWatch in a recent interview.</p><p>It appears some investors are thinking along the same lines, as value and cyclical stocks take off in anticipation of a recovery from the deadly COVID-19 pandemic that has rocked the world for a year. And smaller companies, cogs in the wheels of the economy, have also been rising with the Russell 2000RUT,-1.04%up 18% so far this year.</p><p><img src=\"https://static.tigerbbs.com/0c5bdd22708619636702dcbaabe90f52\" tg-width=\"654\" tg-height=\"342\" referrerpolicy=\"no-referrer\"></p><p>“Smaller companies and mid caps, to an extent as well, are more levered to an expansion in the markets. And that’s why we believe smaller cap companies will do better,” said Ely. He focuses on what he calls “disruptive” stocks of companies that offer a “better, cheaper, faster way of doing things.”</p><p>And Ely appears to have a knack for picking those stocks. Ad-tech group Trade DeskTTD,5.29%and mobile-payments processor SquareSQ,-0.99%,two companieshe highlighted last yearto MarketWatch, returned over 200% each last year. His five-star rated fund, Delaware Smid [small and mid] Cap GrowthDFCIX,+1.09%has had average annual returns of 34% over the past three years and 28% for five years. The fund has been in the top performance quartile of its “midcap growth” peer group for 15 years,according to Morningstar.</p><p>Headed into the pandemic, Ely said it was best to own companies involving crowds or a recovery. “And now that we’re coming back out of it, there’s a couple of areas that we think have particular strengths,” he said.</p><p>His first pick is Pacira BioSciencesPCRX,-0.47%,a maker of non-opioid local anesthesia that plays into a dramatic rebound in medical procedures he sees coming. Knee replacements and similar procedures had been increasing 2% to 4% every year for about 40 years, apart from a flat year between 2008 and 2009. But they fell 15% last year as people avoided hospitals because of COVID-19, notes Ely.</p><p>“We see these coming back. You can’t put off getting your knee done, or your ankle done, or your hip done forever,” he said. Pacira’s products will cut the risk of an opioid addiction, he adds, pointing to data showing 40% of people who end up addicted got there as the result of surgery.</p><p>While opiates have been popular because they’re cheap and get the job done, the playing field for companies like Pacira has been leveled thanks to a bipartisan opiates support bill of a couple of years ago that subsidizes non-opioid anesthesia, he noted.</p><p>His next pick taps into what everyone is looking for — companies levered to consumers or consumer interaction. “I have kids in their late 20s, late teens — they can’t wait to get back out there and go to an event, go back to the gym, go to restaurants, travel, what have you,” he said.</p><p>That leads him to stocks like ride-hailing group LyftLYFT,-2.67%,which he said has been getting costs under control and is specifically leveraged to helping consumers return to those activities. Lyft and rival Uber TechnologiesUBER,-0.56%,which Macquarie owns in larger portfolios, have both “shirked money-losing units, so they’re better prepared to show profits this year,” he said.</p><p>He also owns gym chain Planet FitnessPLNT,-1.17%.“I think after riding a bike indoors or what not for about a year, people are going to want to get back out there,” he said. “Planet Fitness is the largest by far, a clear leader in the value proposition growth area.”</p><p>Ely said he had been watching to see when Planet Fitness shares would start outperforming Peloton InteractivePTON,-0.82%.This is now happening, he notes, with the gym chain up 4% year-to-date and the maker of home-exercise equipment down 22%.</p><p><img src=\"https://static.tigerbbs.com/746ae77eabb740756a5c3121836df0b8\" tg-width=\"647\" tg-height=\"349\" referrerpolicy=\"no-referrer\"></p><p>Planet Fitness has “a lot of upside and fundamentals should improve significantly as we reopen over the next one month, two months, three months,” he said.</p><p>Ely also owns ProgynyPGNY,-1.17%,which he calls “one of the fastest-growing healthcare companies out there.” Progyny is a fertility-benefits provider for companies, with big Silicon Valley names such as MicrosoftMSFT,1.96%and FacebookFB,2.54%on its books.</p><p>“There’s a bunch of trends at play here. First off, people are having babies when they’re older, in general people are having more trouble having babies just flat out, and more and more corporations want to show that they care, and want to help employees in areas that they can. This is a terrific benefit for people to sign up for,” he said.</p><p>Many may have discovered during the pandemic problems with conceiving children, and may be ready to seek that treatment. Progyny did an initial public offering last January, went through the pandemic and did well, but then investors got rattled by some disappointment with revenue, Ely said.</p><p>“There’s nothing wrong with the business, they were just being conservative going into the year, which every company does” he said.</p><p>Ely reiterated the importance of investing early in an economic cycle, set to get kick-started by the recent U.S. fiscal stimulus package. “Right now, we are seven to eight months into a new economic cycle,” he said. Previous bull markets have lasted eight to nine years on average, and equities, notably small companies due to their leverage in an improving economy, tend to perform better, he added.</p><p>“The biggest risk to investors out there right now is not taking risk, [or being] blinded by these stories that the world isn’t going to be great. It’s going to be great, humanity is going to come through this drawdown in a terrific spot,” Ely said.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After winning with ‘disruptive’ stocks, this five-star manager has a few more ideas to share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter winning with ‘disruptive’ stocks, this five-star manager has a few more ideas to share\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-16 23:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/after-winning-with-disruptive-stocks-this-five-star-manager-has-a-few-more-ideas-to-share-11615908335?mod=hp_LATEST&adobe_mc=MCMID%3D64822608045679797911274627916813576001%7CMCORGID%3DCB68E4BA55144CAA0A4C98A5%2540AdobeOrg%7CTS%3D1615909629><strong>marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pacira BioSciences, Planet Fitness and Lyft are among the next hottest stocks, says Macquarie’s Alexander Ely.The world is about to step out of a dark hole and into the bright sunshine, so investors ...</p>\n\n<a href=\"https://www.marketwatch.com/story/after-winning-with-disruptive-stocks-this-five-star-manager-has-a-few-more-ideas-to-share-11615908335?mod=hp_LATEST&adobe_mc=MCMID%3D64822608045679797911274627916813576001%7CMCORGID%3DCB68E4BA55144CAA0A4C98A5%2540AdobeOrg%7CTS%3D1615909629\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.marketwatch.com/story/after-winning-with-disruptive-stocks-this-five-star-manager-has-a-few-more-ideas-to-share-11615908335?mod=hp_LATEST&adobe_mc=MCMID%3D64822608045679797911274627916813576001%7CMCORGID%3DCB68E4BA55144CAA0A4C98A5%2540AdobeOrg%7CTS%3D1615909629","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1115937529","content_text":"Pacira BioSciences, Planet Fitness and Lyft are among the next hottest stocks, says Macquarie’s Alexander Ely.The world is about to step out of a dark hole and into the bright sunshine, so investors should drop the anxiety already.That is the message from Alexander Ely, chief investment officer of U.S. equity growth at Macquarie Investment Management. “The economy is reopening, it’s doing great. We’re coming out of a pandemic. It’s going to be awesome,” he told MarketWatch in a recent interview.It appears some investors are thinking along the same lines, as value and cyclical stocks take off in anticipation of a recovery from the deadly COVID-19 pandemic that has rocked the world for a year. And smaller companies, cogs in the wheels of the economy, have also been rising with the Russell 2000RUT,-1.04%up 18% so far this year.“Smaller companies and mid caps, to an extent as well, are more levered to an expansion in the markets. And that’s why we believe smaller cap companies will do better,” said Ely. He focuses on what he calls “disruptive” stocks of companies that offer a “better, cheaper, faster way of doing things.”And Ely appears to have a knack for picking those stocks. Ad-tech group Trade DeskTTD,5.29%and mobile-payments processor SquareSQ,-0.99%,two companieshe highlighted last yearto MarketWatch, returned over 200% each last year. His five-star rated fund, Delaware Smid [small and mid] Cap GrowthDFCIX,+1.09%has had average annual returns of 34% over the past three years and 28% for five years. The fund has been in the top performance quartile of its “midcap growth” peer group for 15 years,according to Morningstar.Headed into the pandemic, Ely said it was best to own companies involving crowds or a recovery. “And now that we’re coming back out of it, there’s a couple of areas that we think have particular strengths,” he said.His first pick is Pacira BioSciencesPCRX,-0.47%,a maker of non-opioid local anesthesia that plays into a dramatic rebound in medical procedures he sees coming. Knee replacements and similar procedures had been increasing 2% to 4% every year for about 40 years, apart from a flat year between 2008 and 2009. But they fell 15% last year as people avoided hospitals because of COVID-19, notes Ely.“We see these coming back. You can’t put off getting your knee done, or your ankle done, or your hip done forever,” he said. Pacira’s products will cut the risk of an opioid addiction, he adds, pointing to data showing 40% of people who end up addicted got there as the result of surgery.While opiates have been popular because they’re cheap and get the job done, the playing field for companies like Pacira has been leveled thanks to a bipartisan opiates support bill of a couple of years ago that subsidizes non-opioid anesthesia, he noted.His next pick taps into what everyone is looking for — companies levered to consumers or consumer interaction. “I have kids in their late 20s, late teens — they can’t wait to get back out there and go to an event, go back to the gym, go to restaurants, travel, what have you,” he said.That leads him to stocks like ride-hailing group LyftLYFT,-2.67%,which he said has been getting costs under control and is specifically leveraged to helping consumers return to those activities. Lyft and rival Uber TechnologiesUBER,-0.56%,which Macquarie owns in larger portfolios, have both “shirked money-losing units, so they’re better prepared to show profits this year,” he said.He also owns gym chain Planet FitnessPLNT,-1.17%.“I think after riding a bike indoors or what not for about a year, people are going to want to get back out there,” he said. “Planet Fitness is the largest by far, a clear leader in the value proposition growth area.”Ely said he had been watching to see when Planet Fitness shares would start outperforming Peloton InteractivePTON,-0.82%.This is now happening, he notes, with the gym chain up 4% year-to-date and the maker of home-exercise equipment down 22%.Planet Fitness has “a lot of upside and fundamentals should improve significantly as we reopen over the next one month, two months, three months,” he said.Ely also owns ProgynyPGNY,-1.17%,which he calls “one of the fastest-growing healthcare companies out there.” Progyny is a fertility-benefits provider for companies, with big Silicon Valley names such as MicrosoftMSFT,1.96%and FacebookFB,2.54%on its books.“There’s a bunch of trends at play here. First off, people are having babies when they’re older, in general people are having more trouble having babies just flat out, and more and more corporations want to show that they care, and want to help employees in areas that they can. This is a terrific benefit for people to sign up for,” he said.Many may have discovered during the pandemic problems with conceiving children, and may be ready to seek that treatment. Progyny did an initial public offering last January, went through the pandemic and did well, but then investors got rattled by some disappointment with revenue, Ely said.“There’s nothing wrong with the business, they were just being conservative going into the year, which every company does” he said.Ely reiterated the importance of investing early in an economic cycle, set to get kick-started by the recent U.S. fiscal stimulus package. “Right now, we are seven to eight months into a new economic cycle,” he said. Previous bull markets have lasted eight to nine years on average, and equities, notably small companies due to their leverage in an improving economy, tend to perform better, he added.“The biggest risk to investors out there right now is not taking risk, [or being] blinded by these stories that the world isn’t going to be great. It’s going to be great, humanity is going to come through this drawdown in a terrific spot,” Ely said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":171,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":325460875,"gmtCreate":1615914350997,"gmtModify":1704788475794,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/325460875","repostId":"1178891078","repostType":4,"repost":{"id":"1178891078","kind":"news","pubTimestamp":1615909549,"share":"https://ttm.financial/m/news/1178891078?lang=&edition=fundamental","pubTime":"2021-03-16 23:45","market":"us","language":"en","title":"3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=1178891078","media":"Benzinga","summary":"Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on M","content":"<p><b>Roche Holding AG</b>RHHBY 0.17%acquired<b>GenMark Diagnostics, Inc</b>(NASDAQ:&nbsp;GNMK) in a$1.8 billion deal&nbsp;on Monday, the same day&nbsp;<b>Veracyte Inc</b>&nbsp;VCYT 1.76%announcedit completed the&nbsp;acquisition of<b>Decipher Biosciences, Inc.</b></p>\n<p><b>What Happened:</b>With thecancer diagnostic marketexpected to grow to $261.34 billion by 2027 — more than double the $115.60 billion it was worth last year — big biotech companies have been on an acquisition spree to boost their portfolios and&nbsp;technology.</p>\n<p>In January,&nbsp;<b>Exact Sciences Corporation</b>&nbsp;EXAS 3.64%announcedit completed its acquisition of<b>Thrive Earlier Detection Corp.</b>and&nbsp;got Thrive’s&nbsp;blood-based multi-cancer detection technology.</p>\n<p><b>Why It Matters:</b>Early detection of cancer greatly increases the survival rate and smaller biotech companies are showing leadership skills in developing the necessary technology.</p>\n<p>Smaller companies develop specific technology for specific types of cancer which allows them to focus on creating tailored products that are also&nbsp;attractive for larger companies&nbsp;to acquire.</p>\n<p>The following three companies have developed technology that could make them sought-after acquisition targets:</p>\n<p><b>BioMark&nbsp;Diagnostics Inc</b>BMKDF 13.17%, a biotech company headquartered in Vancouver, British Columbia, has developed a state-of-the-art liquid biopsy technology platform for the early detection of cancer. The unique technologyfinds metabolomicsbiomarkers of hard-to-detect cancers of the lung, brain, ovarian and pancreas.</p>\n<p>BioMark&nbsp;is pivoting into commercialization after many years in the research and development phase. On Feb. 16, the company&nbsp;announced&nbsp;it will collaborate with&nbsp;Phytronix&nbsp;Technologies Inc “to advance the development of&nbsp;BioMark’s&nbsp;early lung cancer screening applications using&nbsp;Phytronix-proprietary Laser Diode Thermal Desorption (LDTD) technology,”&nbsp;BioMark&nbsp;said in a press release.</p>\n<p>The collaboration will also support&nbsp;BioMark&nbsp;in setting up clinical lab services in Quebec.&nbsp;BioMark&nbsp;plans to demonstrate its technology later in 2021.</p>\n<p>BioMark’s&nbsp;market cap is $28.67 million and its shares are at 41 cents, up 13.17% on Tuesday morning.</p>\n<p><b>Biocept Inc</b>BIOC 0.17%is another company focusing on early cancer detection through blood-based liquid biopsy. The San Diego-based company has two platforms, CTC&nbsp;and&nbsp;ctDNA, used to detect and analyze a patient’s blood for cancer cells and mutations.</p>\n<p>Biocept boasts22 patentsfor its liquid-biopsy technology in the U.S., EU, Australia, China, Japan and South Korea.</p>\n<p>On Feb. 16, Bioceptannounced&nbsp;its product, Target Selector, is ultra-sensitive and capable of detecting mutations using biopsy specimens&nbsp;usually be deemed “quantity not sufficient.”</p>\n<p>In a pivot brought on by the pandemic, Biocept alsoannounced&nbsp;on Feb. 3&nbsp;its lab had processed 250 000 COVID-19 tests using its RT-PCR technology.</p>\n<p>Biocept has a market cap of $79.98 million and the company's&nbsp;shares are at $5.87, down 1.68% Tuesday morning.</p>\n<p><b>HTG Molecular Diagnostics Inc</b>HTGM 3.29%, an Arizona-based biotech company, developed the EdgeSeq&nbsp;Oncology Biomarker Panel to detect colon, breast, prostate and lung cancer from tumor tissue. The analysis tool can detect2,549 genesassociated with tumor biology and results are available only 36 hours following the biopsy collection.</p>\n<p>Unlike&nbsp;BioMark&nbsp;and Biocept, HTG Molecular uses Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens to test for cancers.</p>\n<p>On Feb. 26, HTG Molecularannouncedits&nbsp;EdgeSeq&nbsp;technology “demonstrated the ability to generate unique gene expression profiles for multiple cancer indications” and the amount of tissue required in the samples was 4 to 8 times less than required for similar tests.</p>\n<p>HTG Molecular has a market cap of $28.82 million and its shares area t $6.17, up 1.48% on Tuesday morning.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-16 23:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on Monday, the same day Veracyte Inc VCYT 1.76%announcedit completed the acquisition ofDecipher ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178891078","content_text":"Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on Monday, the same day Veracyte Inc VCYT 1.76%announcedit completed the acquisition ofDecipher Biosciences, Inc.\nWhat Happened:With thecancer diagnostic marketexpected to grow to $261.34 billion by 2027 — more than double the $115.60 billion it was worth last year — big biotech companies have been on an acquisition spree to boost their portfolios and technology.\nIn January, Exact Sciences Corporation EXAS 3.64%announcedit completed its acquisition ofThrive Earlier Detection Corp.and got Thrive’s blood-based multi-cancer detection technology.\nWhy It Matters:Early detection of cancer greatly increases the survival rate and smaller biotech companies are showing leadership skills in developing the necessary technology.\nSmaller companies develop specific technology for specific types of cancer which allows them to focus on creating tailored products that are also attractive for larger companies to acquire.\nThe following three companies have developed technology that could make them sought-after acquisition targets:\nBioMark Diagnostics IncBMKDF 13.17%, a biotech company headquartered in Vancouver, British Columbia, has developed a state-of-the-art liquid biopsy technology platform for the early detection of cancer. The unique technologyfinds metabolomicsbiomarkers of hard-to-detect cancers of the lung, brain, ovarian and pancreas.\nBioMark is pivoting into commercialization after many years in the research and development phase. On Feb. 16, the company announced it will collaborate with Phytronix Technologies Inc “to advance the development of BioMark’s early lung cancer screening applications using Phytronix-proprietary Laser Diode Thermal Desorption (LDTD) technology,” BioMark said in a press release.\nThe collaboration will also support BioMark in setting up clinical lab services in Quebec. BioMark plans to demonstrate its technology later in 2021.\nBioMark’s market cap is $28.67 million and its shares are at 41 cents, up 13.17% on Tuesday morning.\nBiocept IncBIOC 0.17%is another company focusing on early cancer detection through blood-based liquid biopsy. The San Diego-based company has two platforms, CTC and ctDNA, used to detect and analyze a patient’s blood for cancer cells and mutations.\nBiocept boasts22 patentsfor its liquid-biopsy technology in the U.S., EU, Australia, China, Japan and South Korea.\nOn Feb. 16, Bioceptannounced its product, Target Selector, is ultra-sensitive and capable of detecting mutations using biopsy specimens usually be deemed “quantity not sufficient.”\nIn a pivot brought on by the pandemic, Biocept alsoannounced on Feb. 3 its lab had processed 250 000 COVID-19 tests using its RT-PCR technology.\nBiocept has a market cap of $79.98 million and the company's shares are at $5.87, down 1.68% Tuesday morning.\nHTG Molecular Diagnostics IncHTGM 3.29%, an Arizona-based biotech company, developed the EdgeSeq Oncology Biomarker Panel to detect colon, breast, prostate and lung cancer from tumor tissue. The analysis tool can detect2,549 genesassociated with tumor biology and results are available only 36 hours following the biopsy collection.\nUnlike BioMark and Biocept, HTG Molecular uses Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens to test for cancers.\nOn Feb. 26, HTG Molecularannouncedits EdgeSeq technology “demonstrated the ability to generate unique gene expression profiles for multiple cancer indications” and the amount of tissue required in the samples was 4 to 8 times less than required for similar tests.\nHTG Molecular has a market cap of $28.82 million and its shares area t $6.17, up 1.48% on Tuesday morning.","news_type":1},"isVote":1,"tweetType":1,"viewCount":377,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":355124426,"gmtCreate":1617040586865,"gmtModify":1704801263777,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/355124426","repostId":"2123590172","repostType":4,"isVote":1,"tweetType":1,"viewCount":115,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":324884023,"gmtCreate":1615983079762,"gmtModify":1704789278671,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/324884023","repostId":"1179979737","repostType":4,"isVote":1,"tweetType":1,"viewCount":370,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":346392192,"gmtCreate":1617987143716,"gmtModify":1704705738194,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"Good good&nbsp;","listText":"Good good&nbsp;","text":"Good good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/346392192","repostId":"2126315033","repostType":4,"repost":{"id":"2126315033","kind":"highlight","pubTimestamp":1617981660,"share":"https://ttm.financial/m/news/2126315033?lang=&edition=fundamental","pubTime":"2021-04-09 23:21","market":"us","language":"en","title":"Netflix Grabs Sony's Pay-TV Movie Deal From Starz","url":"https://stock-news.laohu8.com/highlight/detail?id=2126315033","media":"Anders Bylund","summary":"Most Hollywood studios have started their own streaming services to compete in the evolving media market. Sony picked a well-established partner instead.","content":"<p>Video-streaming veteran <b>Netflix</b> (NASDAQ:NFLX) just signed a multiyear content deal with <b>Sony</b> (NYSE:SNE) Pictures Entertainment. Starting in 2022, Sony will move its exclusive pay-TV distribution window from longtime partner <a href=\"https://laohu8.com/S/STRZA\">Starz</a> to Netflix, putting the studio's theatrical releases on Netflix's global streaming platform.</p><p>Sony and Netflix already had a streaming agreement for animated content, but this deal expands that partnership to all genres and production types. Titles making their home entertainment premiere in 2022 on Netflix rather than <b>Lions Gate Entertainment</b> (NYSE:LGF-A) (NYSE:LGF-B) subsidiary <a href=\"https://laohu8.com/S/STRZB\">Starz</a> will include the Brad Pitt thriller <i>Bullet Train</i>, the ensemble-cast action movie <i>Uncharted</i>, and the Reese Witherspoon-produced murder drama <i>Where the Crawdads Sing</i>.</p><p><img src=\"https://static.tigerbbs.com/9243727dc46ddf4fb557f7d44eef1325\" tg-width=\"700\" tg-height=\"534\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><p>Netflix will also distribute future titles in Sony's established film franchises such as <i>Venom</i>, <i>Jumanji</i>, and <i>Bad Boys</i>, as well as any other new projects that Sony's several studio brands may come up with. The deal also allows licensing rights for Netflix to show some titles from Sony's enormous back catalog.</p><p>Furthermore, Netflix gets \"first look\" privilege to consider developing any direct-to-streaming titles Sony's studios may develop during this agreement.&nbsp;Netflix has committed to releasing an undisclosed minimum number of such productions, which will add exclusive Sony/Netflix content on top of Sony's continuing theatrical productions.</p><p>The terms of the deal were not disclosed, but Netflix's payments to Sony should be \"record setting\" for a pay-TV distribution window, according to <i>Variety</i>'s anonymous insider sources.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Netflix Grabs Sony's Pay-TV Movie Deal From Starz</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNetflix Grabs Sony's Pay-TV Movie Deal From Starz\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-09 23:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/09/netflix-grabs-sonys-pay-tv-movie-deal-from-starz/><strong>Anders Bylund</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Video-streaming veteran Netflix (NASDAQ:NFLX) just signed a multiyear content deal with Sony (NYSE:SNE) Pictures Entertainment. Starting in 2022, Sony will move its exclusive pay-TV distribution ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/09/netflix-grabs-sonys-pay-tv-movie-deal-from-starz/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NFLX":"奈飞","QNETCN":"纳斯达克中美互联网老虎指数"},"source_url":"https://www.fool.com/investing/2021/04/09/netflix-grabs-sonys-pay-tv-movie-deal-from-starz/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2126315033","content_text":"Video-streaming veteran Netflix (NASDAQ:NFLX) just signed a multiyear content deal with Sony (NYSE:SNE) Pictures Entertainment. Starting in 2022, Sony will move its exclusive pay-TV distribution window from longtime partner Starz to Netflix, putting the studio's theatrical releases on Netflix's global streaming platform.Sony and Netflix already had a streaming agreement for animated content, but this deal expands that partnership to all genres and production types. Titles making their home entertainment premiere in 2022 on Netflix rather than Lions Gate Entertainment (NYSE:LGF-A) (NYSE:LGF-B) subsidiary Starz will include the Brad Pitt thriller Bullet Train, the ensemble-cast action movie Uncharted, and the Reese Witherspoon-produced murder drama Where the Crawdads Sing.Image source: Getty Images.Netflix will also distribute future titles in Sony's established film franchises such as Venom, Jumanji, and Bad Boys, as well as any other new projects that Sony's several studio brands may come up with. The deal also allows licensing rights for Netflix to show some titles from Sony's enormous back catalog.Furthermore, Netflix gets \"first look\" privilege to consider developing any direct-to-streaming titles Sony's studios may develop during this agreement. Netflix has committed to releasing an undisclosed minimum number of such productions, which will add exclusive Sony/Netflix content on top of Sony's continuing theatrical productions.The terms of the deal were not disclosed, but Netflix's payments to Sony should be \"record setting\" for a pay-TV distribution window, according to Variety's anonymous insider sources.","news_type":1},"isVote":1,"tweetType":1,"viewCount":448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":325460094,"gmtCreate":1615914302918,"gmtModify":1704788475955,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/325460094","repostId":"1115937529","repostType":4,"repost":{"id":"1115937529","kind":"news","pubTimestamp":1615909804,"share":"https://ttm.financial/m/news/1115937529?lang=&edition=fundamental","pubTime":"2021-03-16 23:50","market":"us","language":"en","title":"After winning with ‘disruptive’ stocks, this five-star manager has a few more ideas to share","url":"https://stock-news.laohu8.com/highlight/detail?id=1115937529","media":"marketwatch","summary":"Pacira BioSciences, Planet Fitness and Lyft are among the next hottest stocks, says Macquarie’s Alex","content":"<blockquote>Pacira BioSciences, Planet Fitness and Lyft are among the next hottest stocks, says Macquarie’s Alexander Ely.</blockquote><p>The world is about to step out of a dark hole and into the bright sunshine, so investors should drop the anxiety already.</p><p>That is the message from Alexander Ely, chief investment officer of U.S. equity growth at Macquarie Investment Management. “The economy is reopening, it’s doing great. We’re coming out of a pandemic. It’s going to be awesome,” he told MarketWatch in a recent interview.</p><p>It appears some investors are thinking along the same lines, as value and cyclical stocks take off in anticipation of a recovery from the deadly COVID-19 pandemic that has rocked the world for a year. And smaller companies, cogs in the wheels of the economy, have also been rising with the Russell 2000RUT,-1.04%up 18% so far this year.</p><p><img src=\"https://static.tigerbbs.com/0c5bdd22708619636702dcbaabe90f52\" tg-width=\"654\" tg-height=\"342\" referrerpolicy=\"no-referrer\"></p><p>“Smaller companies and mid caps, to an extent as well, are more levered to an expansion in the markets. And that’s why we believe smaller cap companies will do better,” said Ely. He focuses on what he calls “disruptive” stocks of companies that offer a “better, cheaper, faster way of doing things.”</p><p>And Ely appears to have a knack for picking those stocks. Ad-tech group Trade DeskTTD,5.29%and mobile-payments processor SquareSQ,-0.99%,two companieshe highlighted last yearto MarketWatch, returned over 200% each last year. His five-star rated fund, Delaware Smid [small and mid] Cap GrowthDFCIX,+1.09%has had average annual returns of 34% over the past three years and 28% for five years. The fund has been in the top performance quartile of its “midcap growth” peer group for 15 years,according to Morningstar.</p><p>Headed into the pandemic, Ely said it was best to own companies involving crowds or a recovery. “And now that we’re coming back out of it, there’s a couple of areas that we think have particular strengths,” he said.</p><p>His first pick is Pacira BioSciencesPCRX,-0.47%,a maker of non-opioid local anesthesia that plays into a dramatic rebound in medical procedures he sees coming. Knee replacements and similar procedures had been increasing 2% to 4% every year for about 40 years, apart from a flat year between 2008 and 2009. But they fell 15% last year as people avoided hospitals because of COVID-19, notes Ely.</p><p>“We see these coming back. You can’t put off getting your knee done, or your ankle done, or your hip done forever,” he said. Pacira’s products will cut the risk of an opioid addiction, he adds, pointing to data showing 40% of people who end up addicted got there as the result of surgery.</p><p>While opiates have been popular because they’re cheap and get the job done, the playing field for companies like Pacira has been leveled thanks to a bipartisan opiates support bill of a couple of years ago that subsidizes non-opioid anesthesia, he noted.</p><p>His next pick taps into what everyone is looking for — companies levered to consumers or consumer interaction. “I have kids in their late 20s, late teens — they can’t wait to get back out there and go to an event, go back to the gym, go to restaurants, travel, what have you,” he said.</p><p>That leads him to stocks like ride-hailing group LyftLYFT,-2.67%,which he said has been getting costs under control and is specifically leveraged to helping consumers return to those activities. Lyft and rival Uber TechnologiesUBER,-0.56%,which Macquarie owns in larger portfolios, have both “shirked money-losing units, so they’re better prepared to show profits this year,” he said.</p><p>He also owns gym chain Planet FitnessPLNT,-1.17%.“I think after riding a bike indoors or what not for about a year, people are going to want to get back out there,” he said. “Planet Fitness is the largest by far, a clear leader in the value proposition growth area.”</p><p>Ely said he had been watching to see when Planet Fitness shares would start outperforming Peloton InteractivePTON,-0.82%.This is now happening, he notes, with the gym chain up 4% year-to-date and the maker of home-exercise equipment down 22%.</p><p><img src=\"https://static.tigerbbs.com/746ae77eabb740756a5c3121836df0b8\" tg-width=\"647\" tg-height=\"349\" referrerpolicy=\"no-referrer\"></p><p>Planet Fitness has “a lot of upside and fundamentals should improve significantly as we reopen over the next one month, two months, three months,” he said.</p><p>Ely also owns ProgynyPGNY,-1.17%,which he calls “one of the fastest-growing healthcare companies out there.” Progyny is a fertility-benefits provider for companies, with big Silicon Valley names such as MicrosoftMSFT,1.96%and FacebookFB,2.54%on its books.</p><p>“There’s a bunch of trends at play here. First off, people are having babies when they’re older, in general people are having more trouble having babies just flat out, and more and more corporations want to show that they care, and want to help employees in areas that they can. This is a terrific benefit for people to sign up for,” he said.</p><p>Many may have discovered during the pandemic problems with conceiving children, and may be ready to seek that treatment. Progyny did an initial public offering last January, went through the pandemic and did well, but then investors got rattled by some disappointment with revenue, Ely said.</p><p>“There’s nothing wrong with the business, they were just being conservative going into the year, which every company does” he said.</p><p>Ely reiterated the importance of investing early in an economic cycle, set to get kick-started by the recent U.S. fiscal stimulus package. “Right now, we are seven to eight months into a new economic cycle,” he said. Previous bull markets have lasted eight to nine years on average, and equities, notably small companies due to their leverage in an improving economy, tend to perform better, he added.</p><p>“The biggest risk to investors out there right now is not taking risk, [or being] blinded by these stories that the world isn’t going to be great. It’s going to be great, humanity is going to come through this drawdown in a terrific spot,” Ely said.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After winning with ‘disruptive’ stocks, this five-star manager has a few more ideas to share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter winning with ‘disruptive’ stocks, this five-star manager has a few more ideas to share\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-16 23:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/after-winning-with-disruptive-stocks-this-five-star-manager-has-a-few-more-ideas-to-share-11615908335?mod=hp_LATEST&adobe_mc=MCMID%3D64822608045679797911274627916813576001%7CMCORGID%3DCB68E4BA55144CAA0A4C98A5%2540AdobeOrg%7CTS%3D1615909629><strong>marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pacira BioSciences, Planet Fitness and Lyft are among the next hottest stocks, says Macquarie’s Alexander Ely.The world is about to step out of a dark hole and into the bright sunshine, so investors ...</p>\n\n<a href=\"https://www.marketwatch.com/story/after-winning-with-disruptive-stocks-this-five-star-manager-has-a-few-more-ideas-to-share-11615908335?mod=hp_LATEST&adobe_mc=MCMID%3D64822608045679797911274627916813576001%7CMCORGID%3DCB68E4BA55144CAA0A4C98A5%2540AdobeOrg%7CTS%3D1615909629\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.marketwatch.com/story/after-winning-with-disruptive-stocks-this-five-star-manager-has-a-few-more-ideas-to-share-11615908335?mod=hp_LATEST&adobe_mc=MCMID%3D64822608045679797911274627916813576001%7CMCORGID%3DCB68E4BA55144CAA0A4C98A5%2540AdobeOrg%7CTS%3D1615909629","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1115937529","content_text":"Pacira BioSciences, Planet Fitness and Lyft are among the next hottest stocks, says Macquarie’s Alexander Ely.The world is about to step out of a dark hole and into the bright sunshine, so investors should drop the anxiety already.That is the message from Alexander Ely, chief investment officer of U.S. equity growth at Macquarie Investment Management. “The economy is reopening, it’s doing great. We’re coming out of a pandemic. It’s going to be awesome,” he told MarketWatch in a recent interview.It appears some investors are thinking along the same lines, as value and cyclical stocks take off in anticipation of a recovery from the deadly COVID-19 pandemic that has rocked the world for a year. And smaller companies, cogs in the wheels of the economy, have also been rising with the Russell 2000RUT,-1.04%up 18% so far this year.“Smaller companies and mid caps, to an extent as well, are more levered to an expansion in the markets. And that’s why we believe smaller cap companies will do better,” said Ely. He focuses on what he calls “disruptive” stocks of companies that offer a “better, cheaper, faster way of doing things.”And Ely appears to have a knack for picking those stocks. Ad-tech group Trade DeskTTD,5.29%and mobile-payments processor SquareSQ,-0.99%,two companieshe highlighted last yearto MarketWatch, returned over 200% each last year. His five-star rated fund, Delaware Smid [small and mid] Cap GrowthDFCIX,+1.09%has had average annual returns of 34% over the past three years and 28% for five years. The fund has been in the top performance quartile of its “midcap growth” peer group for 15 years,according to Morningstar.Headed into the pandemic, Ely said it was best to own companies involving crowds or a recovery. “And now that we’re coming back out of it, there’s a couple of areas that we think have particular strengths,” he said.His first pick is Pacira BioSciencesPCRX,-0.47%,a maker of non-opioid local anesthesia that plays into a dramatic rebound in medical procedures he sees coming. Knee replacements and similar procedures had been increasing 2% to 4% every year for about 40 years, apart from a flat year between 2008 and 2009. But they fell 15% last year as people avoided hospitals because of COVID-19, notes Ely.“We see these coming back. You can’t put off getting your knee done, or your ankle done, or your hip done forever,” he said. Pacira’s products will cut the risk of an opioid addiction, he adds, pointing to data showing 40% of people who end up addicted got there as the result of surgery.While opiates have been popular because they’re cheap and get the job done, the playing field for companies like Pacira has been leveled thanks to a bipartisan opiates support bill of a couple of years ago that subsidizes non-opioid anesthesia, he noted.His next pick taps into what everyone is looking for — companies levered to consumers or consumer interaction. “I have kids in their late 20s, late teens — they can’t wait to get back out there and go to an event, go back to the gym, go to restaurants, travel, what have you,” he said.That leads him to stocks like ride-hailing group LyftLYFT,-2.67%,which he said has been getting costs under control and is specifically leveraged to helping consumers return to those activities. Lyft and rival Uber TechnologiesUBER,-0.56%,which Macquarie owns in larger portfolios, have both “shirked money-losing units, so they’re better prepared to show profits this year,” he said.He also owns gym chain Planet FitnessPLNT,-1.17%.“I think after riding a bike indoors or what not for about a year, people are going to want to get back out there,” he said. “Planet Fitness is the largest by far, a clear leader in the value proposition growth area.”Ely said he had been watching to see when Planet Fitness shares would start outperforming Peloton InteractivePTON,-0.82%.This is now happening, he notes, with the gym chain up 4% year-to-date and the maker of home-exercise equipment down 22%.Planet Fitness has “a lot of upside and fundamentals should improve significantly as we reopen over the next one month, two months, three months,” he said.Ely also owns ProgynyPGNY,-1.17%,which he calls “one of the fastest-growing healthcare companies out there.” Progyny is a fertility-benefits provider for companies, with big Silicon Valley names such as MicrosoftMSFT,1.96%and FacebookFB,2.54%on its books.“There’s a bunch of trends at play here. First off, people are having babies when they’re older, in general people are having more trouble having babies just flat out, and more and more corporations want to show that they care, and want to help employees in areas that they can. This is a terrific benefit for people to sign up for,” he said.Many may have discovered during the pandemic problems with conceiving children, and may be ready to seek that treatment. Progyny did an initial public offering last January, went through the pandemic and did well, but then investors got rattled by some disappointment with revenue, Ely said.“There’s nothing wrong with the business, they were just being conservative going into the year, which every company does” he said.Ely reiterated the importance of investing early in an economic cycle, set to get kick-started by the recent U.S. fiscal stimulus package. “Right now, we are seven to eight months into a new economic cycle,” he said. Previous bull markets have lasted eight to nine years on average, and equities, notably small companies due to their leverage in an improving economy, tend to perform better, he added.“The biggest risk to investors out there right now is not taking risk, [or being] blinded by these stories that the world isn’t going to be great. It’s going to be great, humanity is going to come through this drawdown in a terrific spot,” Ely said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":171,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":329351169003736,"gmtCreate":1721413659545,"gmtModify":1721619619802,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a>&nbsp;","text":"$NVIDIA Corp(NVDA)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329351169003736","isVote":1,"tweetType":1,"viewCount":263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":329350552678648,"gmtCreate":1721413634836,"gmtModify":1721619620396,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a>&nbsp;","text":"$NVIDIA Corp(NVDA)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329350552678648","isVote":1,"tweetType":1,"viewCount":74,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":346396833,"gmtCreate":1617986949622,"gmtModify":1704705737226,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"Www","listText":"Www","text":"Www","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/346396833","repostId":"1142324412","repostType":4,"repost":{"id":"1142324412","kind":"news","pubTimestamp":1617982207,"share":"https://ttm.financial/m/news/1142324412?lang=&edition=fundamental","pubTime":"2021-04-09 23:30","market":"us","language":"en","title":"XPeng Inc.: A Reawakening","url":"https://stock-news.laohu8.com/highlight/detail?id=1142324412","media":"seekingalpha","summary":"Valuation is middling but not overvalued like in the past.Recent announcement of capacity expansion in Wuhan lends better operational and sales visibility.Company could breakeven and finally reach positive profits soon; major improvements seen in operating margins.Feared chip shortage  was not a disaster, deliveries are still strong.Government support, China's creation of an EV ecosystem.XPEV's strong deliveries describe not only excellent support from the private sector, but also the Chinese go","content":"<p><b>Summary</b></p>\n<ul>\n <li>Valuation is middling but not overvalued like in the past.</li>\n <li>Recent announcement of capacity expansion in Wuhan lends better operational and sales visibility.</li>\n <li>Company could breakeven and finally reach positive profits soon; major improvements seen in operating margins.</li>\n <li>Feared chip shortage (i.e. supply disruption) was not a disaster, deliveries are still strong.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4e0f3343d69719839f9b8f1d337c3984\" tg-width=\"1536\" tg-height=\"1024\"><span>Photo by Robert Way/iStock Editorial via Getty Images</span></p>\n<p><b>Introduction</b></p>\n<p>The stock price of&nbsp;XPEV&nbsp;has been converging with the performance of the S&amp;P 500 since March 2021, as compared to its massive outperformance in 4Q2020. This could be view positively or negatively. On the bright side, this suggests that price performance would become more predictable with lower volatility, indicative of a broadening consensus on the fundamental prospects of the company. On the other hand, traders may be disappointed its lack of momentum. Therefore, this is probably a good time to stop viewing XPEV as purely a trade, but re-analyze its merits as a fundamentally-driven investment.</p>\n<p><i>The frenetic performance of XPEV has calmed down in recent weeks, allowing its one year performance to track the S&amp;P 500 more closely</i></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9f04001d604ecc7892ef3a76c498578b\" tg-width=\"640\" tg-height=\"236\"><span>Source: SeekingAlpha</span></p>\n<p><i>XPEV's G3 Super Long Range Smart SUV</i></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/68446a741f9f97afc10f2149c4e13e13\" tg-width=\"640\" tg-height=\"388\"><span>Source: XPeng Motors (G3、P7) Intelligent electric car with Internet DNA</span></p>\n<p><b>Industry and commercial positives</b></p>\n<p>Optimism on EVs and&nbsp;strong industry growth&nbsp;rates are common knowledge by now. The following points suggest specific positives for XPEV that remain intact despite relatively ebbing momentum on the stock's price (as compared to 4Q2020):</p>\n<ol>\n <li><b>Deliveries met despite fears on chip shortage.</b>While the stock's price momentum appears to have ebbed, recent news continues to remain positive. At an industry level, Chinese vehicle manufacturers XPEV andNIOmanaged to manufacture the expected numbers of vehicle deliveries, despite much feared chip shortages.XPEV chalked&nbsp;in record quarterly deliveries of 13,340 EVs in Q1 2021, +487% over the year and +130% over the month in March.NIO delivered&nbsp;20,060 +423% over the year while Q1 deliveries rose 15.6% to 20,060. The challenge these EV manufacturers face now is not so much the ability to deliver on its numbers, but on being able to meet high expectations for the stock price to gain further traction.</li>\n <li><b>Government support, China's creation of an EV ecosystem.</b>XPEV's strong deliveries describe not only excellent support from the private sector, but also the Chinese government's push to develop this part of its industry. XPEV has entered into an agreement with the city of Wuhan to build a factory with a capacity of 100,000 EV units. This is a very significant piece of news, considering its deliveries of just 5,102 in March 2021. Annualizing this number, the new capacity will be more than the whole of XPEV's total historical annual production. This news is interesting and significant since it was just released this week, suggesting it may have yet to be factored into analysts' forecast numbers. This is made more important as XPEV has always been considered a laggard in production capabilities to its larger cousin NIO. General Chinese government support for the EV ecosystem is strong, and the new facility in Wuhan echoes earlier provincial government financial support ($77m) in Guangdong. The reality is, for EVs to gain traction, government willingness to support infrastructure initiatives are highly important (e.g. permits for charging stations, creating incentives to convert from old polluting vehicles to green vehicles, etc.). With China's tradition of central planning, the EV ecosystem is placed on the right footing.</li>\n <li><b>Listing in Hong Kong adds to investor base and liquidity.</b>Going forward,XPEV,NIO, and&nbsp;LI&nbsp;intend tolistin Hong Kong this year. This is a strategic move, and makes the valuation of these companies less susceptible by US political bashing (e.g. the threat of being de-listed) should it occur, since it reflects a wider geographical base. The valuations of these companies may even get a boost given greater global liquidity due to added trading in the Asian time zone.</li>\n</ol>\n<p>Of note, in late March, XPEV held an&nbsp;autonomous driving expedition&nbsp;covering eight cities in China and 3,675 kilometers. The exercise was successful, as minimal human intervention was needed during the expedition and adds another brownie point to XPEV's research and development efforts, placing XPEV on the&nbsp;competitive landscape&nbsp;against rivals such as TSLA and NIO on autonomous driving. Apparently, XPEV's autonomous driving results&nbsp;performed better&nbsp;than TSLA's with fewer human interventions per 100km and better navigation in complex situations.</p>\n<p><b>XPEV's improving financials</b></p>\n<p>Now that we have several quarters of financial data on XPEV, it is worth reviewing how its metrics have been performing. Firstly, market expectations aside, deliveries have been very good as abovementioned, and this is flowing through to revenue numbers. As shown in the below table, growth has been very strong, and revenues are expected to more than double in 2021 and continue to double in 2022. Such growth rates place XPEV at the top end of manufacturing firms, as expected of the fast-growing EV market.</p>\n<p>Another point to note is the improvement in operating margins. As with any \"new tech\" company, initial investments would cause hugely negative operating margins in the beginning. What's important is the company's ability to improve margins and reduce costs over time. In this respect, XPEV has done a good job, with operating margins improving sequentially each quarter. Of note, operating margins started to see major improvements between the Jun-2020 (-142%) and Dec-2020 (-39%) quarters as shown in the table below. Given this trend, the company is likely to breakeven and register positive profits soon, which could be a catalytic re-rating for XPEV. When we pair this analysis with the stock price, it appears that XPEV's recently soft stock price performance is not justified.</p>\n<p>Meanwhile, the balance sheet is expected to remain strong. Equity to total liabilities &amp; equity is 23% as at Dec-2020. As abovementioned, further capital raises with a forthcoming Hong Kong listing will add to XPEV's cash buffer.</p>\n<p><i>XPEV's performance improvement in both revenue and operating margin trends appear to have been ignored by the market due to recent the broad market capitulation</i></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f8258dce0cc10e8118a23afce7655bed\" tg-width=\"726\" tg-height=\"737\"><span>*EST = estimate by analysts' consensus from SeekingAlpha</span></p>\n<p><b>XPEV's valuation: somewhere in the middle</b></p>\n<p>XPEV's stock price has done well over the last 6 months versus peers. On a TTM P/S, XPEV is near the middle although its FWD P/S is trading at a premium. However, there could be a general re-rating of the P/S of the sector if the Chinese EV manufacturers reach breakeven in 2021 and record positive profits (our base case belief, given the prevailing trend in XPEV's improving operating margins). This will then allow better price discovery when the companies can then be valued on their P/E ratios.</p>\n<img src=\"https://static.tigerbbs.com/fa975ce545e950a20f809bcc7f698ef6\" tg-width=\"911\" tg-height=\"594\">\n<table>\n <tbody>\n  <tr></tr>\n </tbody>\n</table>\n<p><b>Conclusion and Risks</b></p>\n<p>XPEV's stock price may benefit from two key catalysts: (1) expansion of manufacturing facility in Wuhan, which will concretely raise visibility of revenue growth which is expected to double; (2) a valuation regime change as it progresses from a loss making company to a profitable one, expected by this year. Furthermore, it is worth noting that the valuation is not lofty as compared to price levels in 4Q2020, having fallen over the last couple of months.</p>\n<p>Competition may exist and remain intense, but given the large size of China's market and that there are only a couple of notable players (i.e. NIO, LI), the market remains largely an oligopoly which allows XPEV to retain pricing power.</p>\n<p>Much feared risks of execution in the past appear to have materialized but not in a big way, i.e. the previously expected chip shortage. Given the progression to a post-COVID economy, supply chain links should improve and reduce similar risks in the future.</p>\n<p>On a standalone basis, XPEV's prospects appear bright, and now the key hurdle is whether the NASDAQ will find momentum and exceed previous highs. The base case for this should lean towards the positive as the market is merely in the first year of the economic recovery after the pandemic. Recent price consolidation appears to have created a technical setup for a reawakening of price momentum as consumer activity revives post-pandemic.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XPeng Inc.: A Reawakening</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXPeng Inc.: A Reawakening\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-09 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4418326-xpeng-inc-reawakening><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nValuation is middling but not overvalued like in the past.\nRecent announcement of capacity expansion in Wuhan lends better operational and sales visibility.\nCompany could breakeven and ...</p>\n\n<a href=\"https://seekingalpha.com/article/4418326-xpeng-inc-reawakening\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车"},"source_url":"https://seekingalpha.com/article/4418326-xpeng-inc-reawakening","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1142324412","content_text":"Summary\n\nValuation is middling but not overvalued like in the past.\nRecent announcement of capacity expansion in Wuhan lends better operational and sales visibility.\nCompany could breakeven and finally reach positive profits soon; major improvements seen in operating margins.\nFeared chip shortage (i.e. supply disruption) was not a disaster, deliveries are still strong.\n\nPhoto by Robert Way/iStock Editorial via Getty Images\nIntroduction\nThe stock price of XPEV has been converging with the performance of the S&P 500 since March 2021, as compared to its massive outperformance in 4Q2020. This could be view positively or negatively. On the bright side, this suggests that price performance would become more predictable with lower volatility, indicative of a broadening consensus on the fundamental prospects of the company. On the other hand, traders may be disappointed its lack of momentum. Therefore, this is probably a good time to stop viewing XPEV as purely a trade, but re-analyze its merits as a fundamentally-driven investment.\nThe frenetic performance of XPEV has calmed down in recent weeks, allowing its one year performance to track the S&P 500 more closely\nSource: SeekingAlpha\nXPEV's G3 Super Long Range Smart SUV\nSource: XPeng Motors (G3、P7) Intelligent electric car with Internet DNA\nIndustry and commercial positives\nOptimism on EVs and strong industry growth rates are common knowledge by now. The following points suggest specific positives for XPEV that remain intact despite relatively ebbing momentum on the stock's price (as compared to 4Q2020):\n\nDeliveries met despite fears on chip shortage.While the stock's price momentum appears to have ebbed, recent news continues to remain positive. At an industry level, Chinese vehicle manufacturers XPEV andNIOmanaged to manufacture the expected numbers of vehicle deliveries, despite much feared chip shortages.XPEV chalked in record quarterly deliveries of 13,340 EVs in Q1 2021, +487% over the year and +130% over the month in March.NIO delivered 20,060 +423% over the year while Q1 deliveries rose 15.6% to 20,060. The challenge these EV manufacturers face now is not so much the ability to deliver on its numbers, but on being able to meet high expectations for the stock price to gain further traction.\nGovernment support, China's creation of an EV ecosystem.XPEV's strong deliveries describe not only excellent support from the private sector, but also the Chinese government's push to develop this part of its industry. XPEV has entered into an agreement with the city of Wuhan to build a factory with a capacity of 100,000 EV units. This is a very significant piece of news, considering its deliveries of just 5,102 in March 2021. Annualizing this number, the new capacity will be more than the whole of XPEV's total historical annual production. This news is interesting and significant since it was just released this week, suggesting it may have yet to be factored into analysts' forecast numbers. This is made more important as XPEV has always been considered a laggard in production capabilities to its larger cousin NIO. General Chinese government support for the EV ecosystem is strong, and the new facility in Wuhan echoes earlier provincial government financial support ($77m) in Guangdong. The reality is, for EVs to gain traction, government willingness to support infrastructure initiatives are highly important (e.g. permits for charging stations, creating incentives to convert from old polluting vehicles to green vehicles, etc.). With China's tradition of central planning, the EV ecosystem is placed on the right footing.\nListing in Hong Kong adds to investor base and liquidity.Going forward,XPEV,NIO, and LI intend tolistin Hong Kong this year. This is a strategic move, and makes the valuation of these companies less susceptible by US political bashing (e.g. the threat of being de-listed) should it occur, since it reflects a wider geographical base. The valuations of these companies may even get a boost given greater global liquidity due to added trading in the Asian time zone.\n\nOf note, in late March, XPEV held an autonomous driving expedition covering eight cities in China and 3,675 kilometers. The exercise was successful, as minimal human intervention was needed during the expedition and adds another brownie point to XPEV's research and development efforts, placing XPEV on the competitive landscape against rivals such as TSLA and NIO on autonomous driving. Apparently, XPEV's autonomous driving results performed better than TSLA's with fewer human interventions per 100km and better navigation in complex situations.\nXPEV's improving financials\nNow that we have several quarters of financial data on XPEV, it is worth reviewing how its metrics have been performing. Firstly, market expectations aside, deliveries have been very good as abovementioned, and this is flowing through to revenue numbers. As shown in the below table, growth has been very strong, and revenues are expected to more than double in 2021 and continue to double in 2022. Such growth rates place XPEV at the top end of manufacturing firms, as expected of the fast-growing EV market.\nAnother point to note is the improvement in operating margins. As with any \"new tech\" company, initial investments would cause hugely negative operating margins in the beginning. What's important is the company's ability to improve margins and reduce costs over time. In this respect, XPEV has done a good job, with operating margins improving sequentially each quarter. Of note, operating margins started to see major improvements between the Jun-2020 (-142%) and Dec-2020 (-39%) quarters as shown in the table below. Given this trend, the company is likely to breakeven and register positive profits soon, which could be a catalytic re-rating for XPEV. When we pair this analysis with the stock price, it appears that XPEV's recently soft stock price performance is not justified.\nMeanwhile, the balance sheet is expected to remain strong. Equity to total liabilities & equity is 23% as at Dec-2020. As abovementioned, further capital raises with a forthcoming Hong Kong listing will add to XPEV's cash buffer.\nXPEV's performance improvement in both revenue and operating margin trends appear to have been ignored by the market due to recent the broad market capitulation\n*EST = estimate by analysts' consensus from SeekingAlpha\nXPEV's valuation: somewhere in the middle\nXPEV's stock price has done well over the last 6 months versus peers. On a TTM P/S, XPEV is near the middle although its FWD P/S is trading at a premium. However, there could be a general re-rating of the P/S of the sector if the Chinese EV manufacturers reach breakeven in 2021 and record positive profits (our base case belief, given the prevailing trend in XPEV's improving operating margins). This will then allow better price discovery when the companies can then be valued on their P/E ratios.\n\n\n\n\n\n\nConclusion and Risks\nXPEV's stock price may benefit from two key catalysts: (1) expansion of manufacturing facility in Wuhan, which will concretely raise visibility of revenue growth which is expected to double; (2) a valuation regime change as it progresses from a loss making company to a profitable one, expected by this year. Furthermore, it is worth noting that the valuation is not lofty as compared to price levels in 4Q2020, having fallen over the last couple of months.\nCompetition may exist and remain intense, but given the large size of China's market and that there are only a couple of notable players (i.e. NIO, LI), the market remains largely an oligopoly which allows XPEV to retain pricing power.\nMuch feared risks of execution in the past appear to have materialized but not in a big way, i.e. the previously expected chip shortage. Given the progression to a post-COVID economy, supply chain links should improve and reduce similar risks in the future.\nOn a standalone basis, XPEV's prospects appear bright, and now the key hurdle is whether the NASDAQ will find momentum and exceed previous highs. The base case for this should lean towards the positive as the market is merely in the first year of the economic recovery after the pandemic. Recent price consolidation appears to have created a technical setup for a reawakening of price momentum as consumer activity revives post-pandemic.","news_type":1},"isVote":1,"tweetType":1,"viewCount":145,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":325469037,"gmtCreate":1615914491529,"gmtModify":1704788476601,"author":{"id":"3562320683985663","authorId":"3562320683985663","name":"Ashjng","avatar":"https://static.tigerbbs.com/2e382d6bc7144ee3852451ed21fcb659","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562320683985663","authorIdStr":"3562320683985663"},"themes":[],"htmlText":"HaoDe","listText":"HaoDe","text":"HaoDe","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/325469037","repostId":"1103230244","repostType":4,"isVote":1,"tweetType":1,"viewCount":259,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}